Sumatriptan Tablet
Product Images NDC 68071-4815

3 FDA label images from Nucare Pharmaceuticals,inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Sumatriptan (NDC 68071-4815). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pdp (68071 4815 9)

Pdp (68071 4815 9)
Label for Sumatriptan 50 mg U-D Tablets from NuCare Pharmaceuticals, Inc. This prescription oral tablet package contains 9 tablets. The label includes the NDC 68071-4815-9 and distributor information for Aurobindo Pharma USA, Inc. It displays warnings to keep out of reach of children and storage instructions at controlled temperatures between 59-86°F.*
FDA Label Image

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)
A line graph showing the estimated probability of response over time in minutes from initial dose for different dosages of Sumatriptan (25 mg, 50 mg, 100 mg) and placebo. The graph plots response probability on the vertical axis (0% to 100%) against time on the horizontal axis from 0 to 240 minutes. Higher doses generally show higher response probabilities compared to placebo over time.*
FDA Label Image

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Poo (Sumatriptan Fig2)

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Poo (Sumatriptan Fig2)
A line graph showing the estimated probability of headache remediation or rescue over time in hours from initial dose. The graph compares four groups: placebo, 25 mg, 50 mg, and 100 mg doses of sumatriptan, illustrating increased remediation probability with higher doses over a 24-hour period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.